The Global Rheumatoid Arthritis Market Forecasts to 2012VisiongainMarch 9, 2007 112 Pages - SKU: VSG1491435 |
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)
11/1/2011 | published by: Kalorama Information
Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid
|
more...
|
$3,500.00
|
|
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Celiac Disease - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source
|
more...
|
$3,500.00
|
|
Arthritis - Pipeline Review, H1 2012
1/23/2012 | published by: Global Markets Direct
Arthritis - Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Arthritis - Pipeline Review, H1 2012', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest
|
more...
|
$500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain
|
more...
|
$4,850.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Systemic Lupus Erythematosus – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Rheumatoid Arthritis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Rheumatoid Arthritis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H1 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid
|
more...
|
$500.00
|
|
Gouty Arthritis (Gout) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Gouty Arthritis (Gout) – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2012', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Arthritis Global Clinical Trials Review, H1, 2012
2/20/2012 | published by: GlobalData
Arthritis Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Arthritis Global Clinical Trials Review, H1, 2012 provides data on the Arthritis clinical trial scenario. This report provides elemental information and data relating to the
|
more...
|
$1,000.00
|
|
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market Summary GBI Research, the leading business intelligence provider, has released its latest research “Monoclonal
|
more...
|
$3,500.00
|
Related Markets
Autoimmune Reports
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
- Liver Disease Treatments: The Global Market
- Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
- Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
